EIKN
Eikon Therapeutics, Inc. Common Stock
There isn't enough reported data to score EIKN yet.
EIKN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
EIKN's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
EIKN PE Valuation
EIKN has no meaningful PE right now: it lost money over the past year.
EIKN Forward outlook
There aren't enough analyst estimates for EIKN to show an outlook.
EIKN Earnings Per Share
EIKN Quarterly Revenue
EIKN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$69.6M | -$7.5M |
EIKN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +25.1K shares |
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
EIKN Net Leverage
EIKN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EIKN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.2 | Neutral |
| Stochastic | 7.8 | Oversold |
EIKN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
EIKN PE vs Healthcare Sector
EIKN has no meaningful PE right now: it lost money over the past year.
EIKN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.83 | 12% below |
| 20 week MA | $8.86 | 32% below |
EIKN is in a downtrend: it's below all two of its weekly moving averages, and 32% below its 20-week average.
EIKN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $14.5 | $6.04 | -58% |
It's down 58% so far in 2026.